BRPI0907574A2 - Inibidores de ligação de proteína quinase - Google Patents

Inibidores de ligação de proteína quinase

Info

Publication number
BRPI0907574A2
BRPI0907574A2 BRPI0907574-7A BRPI0907574A BRPI0907574A2 BR PI0907574 A2 BRPI0907574 A2 BR PI0907574A2 BR PI0907574 A BRPI0907574 A BR PI0907574A BR PI0907574 A2 BRPI0907574 A2 BR PI0907574A2
Authority
BR
Brazil
Prior art keywords
protein kinase
binding inhibitors
kinase binding
inhibitors
protein
Prior art date
Application number
BRPI0907574-7A
Other languages
English (en)
Inventor
Willian G Cance
Vita Golubovskaya
David A Ostrov
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of BRPI0907574A2 publication Critical patent/BRPI0907574A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
    • C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0907574-7A 2008-02-18 2009-02-18 Inibidores de ligação de proteína quinase BRPI0907574A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6619208P 2008-02-18 2008-02-18
US6890308P 2008-03-11 2008-03-11
PCT/US2009/001071 WO2009105238A2 (en) 2008-02-18 2009-02-18 Kinase protein binding inhibitors

Publications (1)

Publication Number Publication Date
BRPI0907574A2 true BRPI0907574A2 (pt) 2015-07-21

Family

ID=40986105

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907574-7A BRPI0907574A2 (pt) 2008-02-18 2009-02-18 Inibidores de ligação de proteína quinase

Country Status (10)

Country Link
US (2) US8314150B2 (pt)
EP (1) EP2254566A4 (pt)
JP (1) JP2011512356A (pt)
CN (1) CN102006866B (pt)
AU (1) AU2009215866A1 (pt)
BR (1) BRPI0907574A2 (pt)
CA (1) CA2716015A1 (pt)
EA (1) EA201001321A1 (pt)
MX (1) MX2010009107A (pt)
WO (1) WO2009105238A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139001A2 (en) * 2011-04-08 2012-10-11 Roswell Park Cancer Institute Kinase protein binding inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
DE10047480A1 (de) * 2000-09-26 2002-04-11 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern

Also Published As

Publication number Publication date
EP2254566A2 (en) 2010-12-01
MX2010009107A (es) 2011-02-23
US20130079297A1 (en) 2013-03-28
WO2009105238A3 (en) 2009-11-19
WO2009105238A2 (en) 2009-08-27
CN102006866A (zh) 2011-04-06
CA2716015A1 (en) 2009-08-27
AU2009215866A2 (en) 2010-10-07
US8314150B2 (en) 2012-11-20
JP2011512356A (ja) 2011-04-21
EA201001321A1 (ru) 2011-04-29
US20110065664A1 (en) 2011-03-17
AU2009215866A1 (en) 2009-08-27
EP2254566A4 (en) 2012-01-04
CN102006866B (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI1013623A2 (pt) inibidores de ligação de proteína cinase
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
IL210073A0 (en) Protein kinase inhibitors
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BRPI0920749A2 (pt) proteínas de ligação de antagonista multialvo cd86
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
BRPI0922962A2 (pt) inibidores de p38 map quinase
BRPI0814797A2 (pt) Inibidores dna-pk
EP2136829A4 (en) INHIBITORS OF BINDING TO A PROTEIN KINASE
BRPI0921509A2 (pt) inibidor triazolotiadiazol de proteína quinase c-met
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
BRPI0914557A2 (pt) proteína de ligação de biotina modificada
DK2170891T3 (da) Pyrazolopyrimidinon-kinasehæmmere
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
BRPI0719883A2 (pt) Inibidores de quinase
BRPI0907574A2 (pt) Inibidores de ligação de proteína quinase
LTPA2019004I1 (lt) Baltymų kinazės slopikliai

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.